XML 78 R69.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details)
€ / shares in Units, € in Millions
 6 Months Ended
Jun. 30, 2025
EUR (€)
shares
€ / shares
Restricted Share Plan 2024  
Disclosure of classes of share capital [Line Items]  
Service period 3 years
Restricted Share Plan 2025  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 4,021,370
Fair value of plan at the date of grant | € € 331
Restricted Share Plan 2025 | Without market condition  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 2,599,478
Fair value per share awarded (in euros per share) | € / shares € 83.94 [1]
Restricted Share Plan 2025 | With market condition  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 1,421,892
Restricted Share Plan 2025 | With market condition | Excluding General Director  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 1,331,892
Fair value per share awarded (in euros per share) | € / shares € 79.25 [2]
Restricted Share Plan 2025 | With market condition | Chief Executive Officer  
Disclosure of classes of share capital [Line Items]  
Total number of shares awarded (in shares) 90,000
Fair value per share awarded (in euros per share) | € / shares € 75.1 [2]
[1] Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.
[2] Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.